The obesity drug industry is entering a new phase of competition. The first wave was dominated by GLP-1 receptor agonists such as semaglutide, followed by dual GLP-1/GIP agonists such as tirzepatide. The next competitive frontier is moving toward triple agonists, oral GLP-1 therapies, longer-acting medicines, combination approaches and treatments designed to address obesity-related cardiovascular, metabolic, liver and sleep disorders.

The opportunity is expanding beyond weight loss alone. Pharmaceutical companies are competing on magnitude of weight reduction, durability, dosing frequency, oral convenience, cardiometabolic outcomes, manufacturing scale, affordability, payer access and treatment persistence.

Explore the Full Research Scope: https://www.towardshealthcare.com/download-sample/5410

The scale of unmet need remains enormous. CDC data show that 40.3% of U.S. adults had obesity during August 2021–August 2023, while 9.4% had severe obesity. The CDC’s 2024 state-level maps also found that every U.S. state and territory had an adult obesity prevalence of at least 25%.

At the same time, the commercial race is accelerating. Novo Nordisk reported that its obesity portfolio reached 3.6 million people worldwide in 2025, while Eli Lilly reported $4.16 billion in U.S. Zepbound revenue in Q1 2026, up 79% year over year.

The next major disruption could come from retatrutide, Lilly’s investigational GLP-1/GIP/glucagon triple agonist, which produced up to 28.3% average weight loss at 80 weeks in the TRIUMPH-1 Phase 3 trial. Lilly plans to submit a BLA to the FDA in Q1 2027.

1. Why the Obesity Drug Race Is Changing

The obesity treatment landscape has evolved rapidly.

First generation: GLP-1

Semaglutide-based medicines established GLP-1 therapy as a major pharmacological approach to chronic weight management.

Wegovy (semaglutide) is FDA-approved for chronic weight management and, since 2024, also has an indication to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight. In the FDA-reviewed SELECT trial, major adverse cardiovascular events occurred in 6.5% of participants receiving Wegovy compared with 8.0% receiving placebo.

Second generation: GLP-1 + GIP

Zepbound (tirzepatide) moved the field toward dual incretin activity.

The FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. Tirzepatide activates both GLP-1 and GIP receptors, reducing appetite and food intake.

The indication has subsequently expanded beyond weight management. In December 2024, FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, creating an additional commercial opportunity around obesity-related comorbidities.

Third generation: GLP-1 + GIP + glucagon

The next potential leap is represented by retatrutide, an investigational triple receptor agonist targeting GLP-1, GIP and glucagon.

Lilly’s Phase 3 TRIUMPH-1 data showed average weight loss of 28.3% at 80 weeks at the 12 mg dose, while 45.3% of participants achieved at least 30% weight loss.

This could move the competitive conversation from:

“Can obesity be treated pharmacologically?”

to:

“How much weight loss, how quickly, how durably and with what impact on obesity-related disease can pharmacotherapy deliver?”

2. Global Obesity Drug Opportunity: TAM, SAM and SOM

Public sources do not provide a single standardized global revenue definition for the entire “GLP-1 obesity drug market.” Therefore, a strategic TAM/SAM/SOM framework is more useful when based on the addressable patient population and current treatment penetration.

TAM — Total Addressable Population

Novo Nordisk estimates that almost 1 billion people globally are living with obesity, while its 2025 annual report indicates that only around 2% were receiving treatment.

This creates an enormous treatment-access gap.

Strategic TAM: ~1 billion people living with obesity globally

This should not be interpreted as 1 billion immediately eligible for every GLP-1 or incretin drug. Eligibility depends on BMI, comorbidities, age, regulatory labels, clinical guidelines and payer policies.

SAM — Serviceable Addressable Market

The U.S. represents one of the most commercially developed obesity-drug markets.

CDC/NCHS data show that 40.3% of U.S. adults had obesity during August 2021–August 2023, representing more than 100 million adults based on the CDC’s population estimates. Severe obesity affected 9.4% of adults.

The practical U.S. SAM therefore includes adults who:

• Meet obesity or overweight treatment criteria
• Have qualifying comorbidities
• Are medically appropriate for pharmacotherapy
• Can access a prescriber
• Have insurance or sufficient self-pay capacity
• Can obtain the product through legitimate channels

SOM — Currently Captured Opportunity

The existing treated population is still small relative to the potential addressable population.

Novo Nordisk reported that its obesity portfolio reached 3.6 million people worldwide in 2025, despite the global obesity population approaching 1 billion.

This highlights the difference between:

TAM → people who could potentially benefit

SAM → people commercially and clinically addressable

SOM → people actually reached by a specific product/company

For pharmaceutical companies, the biggest growth opportunity may therefore come not only from switching patients between competing drugs, but also from bringing previously untreated patients into pharmacological obesity care.

3. Consumer Behaviour Is Becoming a Major Competitive Factor

The obesity-drug consumer is changing.

Historically, patients often viewed obesity treatment through lifestyle modification, bariatric surgery or older pharmacological approaches.

GLP-1 therapy has changed expectations around:

• Weight-loss magnitude
• Convenience
• Dosing frequency
• Cardiovascular benefits
• Comorbidity management
• Digital health support
• Long-term maintenance
• Out-of-pocket affordability

Oral treatment could expand the consumer pool

Novo Nordisk reported that its Wegovy pill surpassed 3 million prescriptions in the U.S. after its January 2026 launch, with the majority of new prescriptions going to people who were new to GLP-1 therapy.

This is strategically important.

It suggests that route of administration can influence treatment adoption, not simply clinical efficacy.

A once-daily oral therapy may appeal to consumers who:

• Dislike injections
• Prefer conventional oral medicines
• Want greater treatment discretion
• Are hesitant about injectable therapy
• Are new to obesity pharmacotherapy

Therefore, future competition will increasingly involve patient experience, not just percentage weight loss.

4. Buyer Intelligence: Who Actually Controls the Obesity Drug Purchase?

The buyer ecosystem is broader than the patient.

1. Patients

Patients increasingly evaluate:

• Weight-loss expectations
• Side effects
• Monthly cost
• Injection versus oral treatment
• Convenience
• Speed of results
• Long-term maintenance
• Cardiovascular and metabolic benefits

2. Physicians

Primary-care physicians, endocrinologists, obesity specialists, cardiologists and other specialists can influence treatment selection.

Physician decision-making increasingly depends on:

efficacy + safety + comorbidity benefits + affordability + formulary access + patient persistence.

3. Payers

Payers represent one of the biggest commercial gatekeepers.

Prior authorization, formulary placement, eligibility requirements, rebates and net pricing can determine whether a patient actually receives a prescription.

4. Government

CMS has become a major strategic factor.

Beginning July 1, 2026, CMS launched the Medicare GLP-1 Bridge, providing eligible Medicare Part D beneficiaries access to certain GLP-1 medicines for weight management at a $50 monthly copay.

CMS currently lists Foundayo, Wegovy and Zepbound KwikPen as eligible products under the Bridge for weight-management use.

CMS also states that participating manufacturers provide eligible drugs at a $245 net price per monthly supply under the Bridge.

This creates an important buyer-intelligence signal:

Access strategy and net pricing can become as important as clinical differentiation.

5. GLP-1 Volume and Commercial Momentum

The commercial data demonstrate how quickly the category is scaling.

Eli Lilly

In Q1 2026:

• Worldwide revenue: $19.8 billion
• Worldwide revenue growth: 56%
• Company-wide volume growth: 65%
• Zepbound revenue: $4.16 billion
• U.S. Zepbound revenue growth: 79%
• Mounjaro worldwide revenue: $8.66 billion

The numbers show that incretin therapies are not simply a promising pipeline category—they are already major pharmaceutical revenue engines.

Novo Nordisk

Novo Nordisk reported:

• 3.6 million people reached by its obesity portfolio in 2025
• 31% obesity portfolio sales growth at constant exchange rates
• Wegovy available in 52 countries by the end of 2025
• New higher-dose and oral Wegovy offerings expanding the portfolio.

The competitive battlefield is therefore moving from individual blockbuster products toward multi-product obesity franchises.

6. The Triple-Agonist Race

The most closely watched next-generation asset is retatrutide from Eli Lilly.

Retatrutide is an investigational:

GLP-1 + GIP + glucagon receptor agonist

In the TRIUMPH-1 Phase 3 trial, the 12 mg dose produced:

• 28.3% average weight loss at 80 weeks
• 70.3 lb average weight loss
• 45.3% of participants achieving ≥30% weight loss

Additional Phase 3 results strengthened the program.

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes lost up to 20.8% of body weight at 80 weeks.

In TRIUMPH-3, participants with severe obesity and established cardiovascular disease lost up to 22.6% at 80 weeks.

Lilly has stated that it plans to submit a BLA for retatrutide to the FDA in Q1 2027.

The competitive significance is substantial.

If approved, retatrutide could challenge the current efficacy benchmark and potentially create another major step-change in obesity pharmacotherapy.

7. The Next Competitive Threats Beyond Retatrutide

The pipeline is becoming increasingly diversified.

Novo Nordisk — CagriSema

CagriSema combines:

cagrilintide + semaglutide

Novo Nordisk reported 23% weight loss after 84 weeks in REDEFINE 4, but the trial did not meet its primary non-inferiority endpoint against tirzepatide 15 mg. The company is also planning a higher-dose CagriSema program.

This demonstrates that the next generation will not automatically win simply because it is a combination therapy.

Head-to-head efficacy matters.

Amgen — MariTide

Amgen’s MariTide (maridebart cafraglutide/AMG 133) is an antibody-peptide conjugate that activates GLP-1 receptors while antagonizing GIP receptors.

Its differentiated feature is dosing frequency.

Amgen is studying MariTide in Phase 3 programs involving obesity, type 2 diabetes, cardiovascular disease, heart failure and obstructive sleep apnea, including programs exploring monthly, every-eight-week and quarterly administration.

This introduces another competitive dimension:

What if patients do not need a weekly injection?

Oral GLP-1 Competition

Eli Lilly’s orforglipron demonstrated meaningful weight loss in Phase 3 development. In ATTAIN-1, the highest dose produced an average 12.4% weight loss at 72 weeks.

Oral medicines could materially expand the treatment funnel by reducing injection aversion and simplifying administration.

8. FDA and Regulatory Competition

The FDA landscape is becoming increasingly important for competitive strategy.

Wegovy

FDA has approved Wegovy for chronic weight management and for reducing major cardiovascular events in specified adults with cardiovascular disease and overweight or obesity.

Zepbound

FDA approved Zepbound for chronic weight management in 2023 and subsequently approved it for moderate-to-severe obstructive sleep apnea in adults with obesity.

Compounding and supply

Regulatory competition is also extending to compounded GLP-1 products.

In February 2026, FDA announced its intent to take action against mass marketing of non-FDA-approved compounded GLP-1 products.

In April 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substance list, stating that it had not identified a clinical need for outsourcing facilities to compound those substances from bulk ingredients.

For branded manufacturers, this can influence:

volume → pricing → supply → channel strategy → patient acquisition → brand trust.

9. Import & Export Intelligence: Why Trade Data Needs Careful Interpretation

GLP-1 import/export analysis presents an important data challenge.

Products such as semaglutide and tirzepatide are not generally represented in public trade statistics as a single, clean “GLP-1 obesity drugs” category.

U.S. trade statistics are organized using HTS classifications, while pharmaceutical products can involve finished dosage forms, active pharmaceutical ingredients, intermediates, devices and packaging.

The U.S. International Trade Commission states that its DataWeb provides official U.S. import and export statistics from the Department of Commerce and Census Bureau and allows users to analyze trade by product classification and period.

Therefore, pharmaceutical trade intelligence should distinguish between:

Finished drug imports

Pre-filled pens, tablets, vials and other finished products.

API imports

Active pharmaceutical ingredients such as peptide-based substances.

Manufacturing inputs

Specialized chemicals, excipients, devices and packaging components.

Contract manufacturing

Cross-border manufacturing and fill-finish activities.

A key research limitation is that official trade data should not be presented as “semaglutide imports” or “tirzepatide exports” unless the underlying HTS classification specifically supports that conclusion.

This is critical for reliable market intelligence.

10. Manufacturing Volume Is Becoming a Competitive Weapon

The obesity drug race is no longer only an R&D race.

It is also a manufacturing race.

Companies must solve:

• Peptide manufacturing
• API capacity
• Device production
• Fill-finish capacity
• Cold-chain logistics
• Quality control
• Global distribution
• Inventory management
• Supply continuity

Novo Nordisk reported that its oral Wegovy is being produced domestically in the U.S., with API manufactured at its Clayton, North Carolina facility and tablets manufactured and packaged at its Durham, North Carolina site.

For companies competing in obesity, manufacturing capacity can become a strategic barrier to entry.

11. Competitive Landscape

The obesity drug race now includes several distinct strategic positions.

Novo Nordisk

Key assets include:

• Wegovy
• Ozempic
• Rybelsus
• CagriSema
• Higher-dose semaglutide
• Oral Wegovy
• Zenagamtide

Novo Nordisk’s strategy is increasingly focused on building a broader cardiometabolic franchise rather than relying on a single injectable product.

Eli Lilly

Key assets include:

• Zepbound
• Mounjaro
• Orforglipron
• Retatrutide

Lilly is competing across injectable dual agonists, oral GLP-1 therapy and next-generation triple agonism.

Amgen

Key asset:

• MariTide

Amgen’s differentiation is centered on long-acting biology and less-frequent dosing.

Pfizer

Pfizer remains active in obesity research despite discontinuing danuglipron development. The company stated that it continues to pursue other obesity programs, including an oral GIP receptor antagonist candidate.

Structure Therapeutics

Structure Therapeutics is developing GSBR-1290, an oral GLP-1 receptor agonist program targeting obesity and type 2 diabetes, with development plans extending into pivotal-stage studies.

12. What Will Win the Next Obesity Drug Race?

The next blockbuster is unlikely to be determined by weight loss alone.

Five competitive variables are becoming critical.

1. Efficacy

Can the drug deliver 15%, 20%, 25% or greater sustained weight loss?

2. Durability

Can patients maintain weight reduction over several years?

3. Convenience

Weekly injections may increasingly compete with:

• Daily oral pills
• Monthly injections
• Every-eight-week dosing
• Quarterly dosing

4. Comorbidity benefits

The strongest products may become platforms for managing:

• Cardiovascular disease
• Type 2 diabetes
• Obstructive sleep apnea
• MASH
• Chronic kidney disease
• Heart failure
• Osteoarthritis

5. Affordability and access

Clinical superiority is not enough if patients cannot obtain the medicine.

The CMS GLP-1 Bridge demonstrates how reimbursement policy and net pricing can materially change access.

13. GTM Strategy for the Next Generation of Obesity Drugs

A successful go-to-market strategy should be built around multiple customer segments.

Segment 1: Treatment-naïve patients

Position around:

convenience + safety + clinically meaningful weight loss

The rapid adoption of the Wegovy pill among people new to GLP-1 therapy demonstrates the potential of this segment.

Segment 2: Existing GLP-1 users

Position around:

greater efficacy + better tolerability + convenience + improved maintenance

This will become particularly important when triple agonists reach commercialization.

Segment 3: Patients with comorbidities

Develop indication-specific strategies around:

• Cardiovascular disease
• OSA
• MASH
• Diabetes
• CKD
• Heart failure

Segment 4: Payers

Demonstrate:

clinical outcomes + healthcare utilization reduction + cost-effectiveness + long-term disease management.

Segment 5: Physicians

Provide evidence that simplifies treatment selection and patient management.

14. Patent and Competitive Intelligence Will Become More Important

As the category matures, the competitive battle will increasingly involve intellectual property.

Companies should monitor:

• Composition-of-matter patents
• Formulation patents
• Combination patents
• Dosing patents
• Delivery technology
• Oral formulations
• Long-acting formulations
• Manufacturing patents
• Device patents
• Patent expiry
• Generic/biosimilar implications
• Patent litigation
• Freedom-to-operate risks

For triple agonists, the IP landscape could become particularly important because companies are competing around multi-receptor activity, molecular design, dosing schedules and formulation technologies.

15. Strategic Buyer Intelligence: What Pharmaceutical Companies Should Track

For business development and competitive strategy teams, the obesity drug race should be monitored through a structured intelligence framework:

Clinical Intelligence

Which assets are producing the strongest weight-loss and comorbidity outcomes?

Pipeline Intelligence

Which Phase 2 and Phase 3 programs are approaching regulatory submission?

Regulatory Intelligence

Which FDA decisions, label expansions and safety developments could change the competitive landscape?

Patent Intelligence

Which molecules, formulations and delivery technologies have defensible IP?

Commercial Intelligence

Which companies are gaining prescription volume and market access?

Payer Intelligence

Which plans cover obesity treatment and what utilization controls are being applied?

Consumer Intelligence

Are patients switching because of efficacy, side effects, price, convenience or dosing frequency?

Manufacturing Intelligence

Which companies have sufficient API, device and fill-finish capacity to support global launches?

16. The Big Question: What Comes After GLP-1?

The obesity drug race is moving from a single-mechanism competition toward a broader cardiometabolic platform competition.

The progression is becoming:

GLP-1 → GLP-1/GIP → GLP-1/GIP/Glucagon → combinations → oral therapies → long-acting therapies → multi-indication cardiometabolic platforms

The winners will likely be the companies that combine:

high efficacy + durable weight loss + convenient dosing + strong safety + cardiovascular/metabolic benefits + scalable manufacturing + payer access.

The emergence of retatrutide, CagriSema, MariTide and oral GLP-1 programs suggests that the next generation of obesity therapies could be substantially more competitive than today’s GLP-1 landscape.

17. What This Means for Pharma and Biotech Companies

For pharmaceutical companies entering or competing in obesity, simply tracking Wegovy versus Zepbound is no longer enough.

A complete competitive intelligence program should connect:

Pipeline → Clinical Trials → FDA → Patents → Manufacturing → Physicians → Payers → Pricing → Consumer Behaviour → Distribution → Launch → Post-launch Performance

The strategic question is changing from:

“Who has the best GLP-1?”

to:

“Who can build the most scalable, clinically differentiated and commercially accessible obesity-treatment platform?”

That distinction could determine the next generation of blockbuster obesity medicines.